

Date: 03/20/2026 Start time: 3:00pm (ET) End time: 5:00pm (ET)

Advarra IBC meetings are closed to the public to protect confidential and proprietary information as outlined in the Advarra IBC standard operating procedures.

Chair: Warren Rummage

Voting Members Present: Dan Eisenman (Committee Member), Scott Swindle (Committee Member), Darlene Ward (Committee Member), Nichole Tower (Committee Member), Aparupa Sengupta (Committee Member), Jenna Mckenzie (Committee Member), Amy Diaz (Community Member)

Other Persons Present: [REDACTED]

Conflict of Interest: The IBC Chair queried the IBC to identify any potential conflicts of interest and requested that any potential conflicts of interest be disclosed to the IBC. The IBC Chair then reminded the IBC that if any potential conflicts of interest were identified as the meeting progressed, disclosure would need to occur at that time. Identified potential conflict of interest: Yes No

Study Summary Information for Minutes

Protocol #	IBC Study Submission ID #
[REDACTED]	PROTO202600022
Study Title	A Multi-Center, Randomized, Double-Masked, Active-Comparator-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of [REDACTED] in Participants with Neovascular Age-Related Macular Degeneration (
Agent	Adeno-Associated Virus (AAV)
Agent Characteristics	Replication deficient vector; Risk Group 1
rDNA Category	III-C-1
Description of Recombinant Nucleic Acid Sources	<ul style="list-style-type: none"> [REDACTED] Recombinant AAV comprised [REDACTED]

Description of Genetically Modified Microbes or Vectors	<ul style="list-style-type: none"> • Replication-deficient Adeno-associated virus (AAV)
Description of Transgene Expression	<ul style="list-style-type: none"> • [REDACTED]
Risk Assessment of Procedures	<ul style="list-style-type: none"> • Preparation of Dose <ul style="list-style-type: none"> ○ Sharps Safety ○ Standard Precautions • Administered Injection into the Eye <ul style="list-style-type: none"> ○ Sharps Safety ○ Standard Precautions • Dispose of all materials as biohazardous waste

Site Information

Site Name	Envision Ocular, LLC - Bloomfield, NJ	IBC Site Submission ID #	SAF202600112
PI Name	Patrick Higgins, MD		
Site Biosafety Level	BSL2		
Staff Training Verified by PI Signed SOP	<input checked="" type="checkbox"/> Yes	<input type="checkbox"/> No	

Motions, Votes, and Committee's Decision

Motion: Approve			
Conditions: N/A			
Motion	First: [REDACTED]	Second: [REDACTED]	
Votes	For: 8	Against: 0	Abstained: 0

Chair Signature

Approved by Chair:

Name: Warren Rummage

Date: 2026/03/31